In a patient-survey study, we show the dramatic benefits of dipyridamole for treating pterygium, pinguecula and related dry eye disease.

Anti heart attack drug is found useful in treating multiple eye disorders. Our comprehensive review is published.

LDN, the novel treatment for which we published the first-ever trial in 2007, reaches 300,000 users. We revamp our popular site.

Each year over 30 million people worldwide are exposed to gadolinium contrast during MRI scans. Our study reveals the unknown dangers.

With researchers at St. George’s University in London, we reveal how rituximab may treat metastatic prostate cancer.

One of our collaborators donated blood for our experiment, and in the process we discovered they had an early state rare stomach tumor.

First-ever non-surgical treatment (dipyrdiamole) discovered for common eye disorders, pterygium and pinguecula – under MedInsight’s leadership.

We report long term survival (over 10 years after cure) of two children with liver cancer utilizing a novel safe treatment.

In a joint study with Lille University, we reveal the mechanism of action how gallium stops bleeding from wounds.

We publish a comprehensive study of all the anti-cancer uses of the Japanese anti-allergy drug, Tranilast.

In this comprehensive review, we summarize all the studies using intravenous immunoglobulin (IVIG) for treating Crohn’s disease.

We review the multiple therapeutic benefits of a safe Japanese hair loss drug, including its multiple anti-cancer effects.

Gallium, an old and well known mineral, is found to rapidly halt bleeding from wounds. Our case series is published.

We show that a simple blood test can replace the need for a biopsy in determining the potential of chemotherapy in pancreatic cancer.

With University of California San Diego, we show the effect of an old cough medicine, noscapine, in preventing prostate cancer spread.

MedInsight launches a physician & patient educatonal website about LDN – a novel treatment for autoimmune diseases and cancer.

A non-addictive opium-derived drug fights prostate cancer, our breakthrough study shows.

With our Penn State University colleagues, we uncover the long-sought reason why a popular skin-cancer drug works.

In world-first, we show that a low-dose of an addiction drug can safely treat Crohn’s disease. Study carried out at Hershey Medical Center.

MedInsight Research Institute is founded by David Youlton and Moshe Rogosnitzky, as a non-profit organization.